LYRFIGTU
Oct 12, 2026
FGFR Inhibitors: How a Once-Overlooked Target Became Precision Oncology’s Next Big Story
Summary FGFR has evolved into a clinically validated oncology target, progressing from a relatively overlooked pathway to an important biomarker-driven treatment strategy across multiple solid tumors. Cholangiocarcinoma is the leading success story for FGFR-targeted therapy. FGFR2 fusions/rearrangements occu...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
